Etana Biotechnologies established its biopharmaceutical manufacturing facility in Jakarta. Etana is involved in developing a variety of innovative therapeutics, like vaccines, cancer drugs, and other biological products. The new facility, which has the latest technological facilities, quality systems with international standards, will allow Etana to produce its own messenger-RNA vaccine, the first in the ASEAN region. This plant features cutting-edge technology, quality processes that meet worldwide standards and has been accredited by Indonesia’s National Agency of Drug and Food Control with Good Manufacturing Practices (CPOB).
Through technology transfer, Etana will develop a COVID-19 vaccine using an mRNA platform in conjunction with Chinese businesses Yuxi Walvax Biotechnology and Suzhou Abogen Biosciences. Etana can also use this technology to create the first locally made Covid-19 vaccine in Indonesia, called InaRNAVac.
Etana intends to develop its multiplatform drug substance production facilities for monoclonal antibodies and adenoviruses. Etana will also create Erythropoietin (EPO), which is required in dialysis therapy. Following that, the company intends to produce an adenovirus platform for vaccine manufacturing. The output is meant to fulfill domestic demands and will be sold to the ASEAN market and worldwide.
(Source: Biosprectrum Asia)